16:38 , Jul 18, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibition of BACH1 or the genes it controls for metastatic lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Inhibiting the pro-metastatic transcription factor BACH1 or its gene targets MCT1, HMOX1, HK2 and GADPH could treat metastatic lung cancer. In patients with metastasized lung cancer, levels of BACH1...
21:35 , Apr 17, 2019 |  BC Extra  |  Preclinical News

Atomwise unveils Chagas disease compounds from AIMS program

Atomwise has revealed the first hit identifications by two of its AIMS program collaborators, including compounds against an unexploited target for Chagas disease, for which there are few therapies. On Tuesday, Atomwise Inc. (San Francisco,...
17:56 , Aug 29, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays An epigenetic-based method of quantifying blood cell types could aid the differential diagnosis of immunodeficiencies such as severe combined immunodeficiency (SCID). The method involves four steps: treating DNA isolated from patient blood...
20:11 , Apr 26, 2018 |  BC Innovations  |  Translation in Brief

Modulating metabolism in MS

Johns Hopkins University researchers showed in Science Tecfidera dimethyl fumarate blocks aerobic glycolysis by inhibiting glyceraldehyde-3-phosphate dehydrogenase (GAPDH), shedding light on how the multiple sclerosis drug suppresses immune activation and suggesting metabolism as a target...
21:13 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling; tissue markers Tumor levels of a panel of 13 glycolysis-related genes could help predict responses to adoptive T cell therapies in melanoma patients. In tumors from an undisclosed number of melanoma patients...
13:33 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

Santhera's congenital muscular dystrophy candidate well tolerated in Phase I

Santhera Pharmaceuticals Holding AG (SIX:SANN) reported data from the Phase I CALLISTO trial in 20 ambulatory and non-ambulatory patients ages 5-16 with congenital muscular dystrophy showing that once-daily 0.02-0.08 mg/kg doses of oral omigapil (SNT-317,...
17:56 , Nov 1, 2017 |  BC Innovations  |  Translation in Brief

A window to Warburg

A study from Duke University suggests GAPDH inhibition could kill cancers that depend on the Warburg effect without upending normal cell metabolism. The authors homed in on the target via metabolic control analysis, and found...
07:00 , Sep 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Plasmodium glyceraldehyde-3-phosphate dehydrogenase (GAPDH)

Infectious disease INDICATION: Malaria In vitro and mouse studies suggest inhibiting Plasmodium GAPDH could help treat malaria. In primary macrophages incubated with P. berghei sporozoites, two antibodies against P. berghei GAPDH decreased sporozoite entry into...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Santhera musculoskeletal news

Santhera received a $246,000 grant from FDA under its Orphan Products Grants Program to support the ongoing open-label, dose-escalation, U.S. Phase I CALLISTO trial evaluating omigapil in ambulatory and non-ambulatory patients with congenital muscular dystrophy....
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

Omigapil: Completed Phase I enrollment

Santhera completed enrollment of 20 ambulatory and non-ambulatory patients ages 5-16 in the open-label, dose-escalation, U.S. Phase I CALLISTO trial evaluating 0.02, 0.08 and 0.2 mg/kg/day oral omigapil for 12 weeks. In 2007, the company...